List of Excipients in Branded Drug ACTOS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ACTOS	pioglitazone hydrochloride	54868-4343	CARBOXYMETHYLCELLULOSE CALCIUM
Physicians Total Care Inc	ACTOS	pioglitazone hydrochloride	54868-4343	HYDROXYPROPYL CELLULOSE
Physicians Total Care Inc	ACTOS	pioglitazone hydrochloride	54868-4343	LACTOSE MONOHYDRATE

Actos Excipient Strategy and Commercial Opportunities for Pioglitazone

Last updated: August 13, 2026

Actos is an immediate-release pioglitazone tablet whose core excipients are conventional, low-cost oral solid-dose materials. The commercial opportunity is therefore not an Actos-specific excipient patent position. It is the development of differentiated pioglitazone products that improve tolerability, swallowability, dose flexibility, stability, or combination-product economics after the core compound patent expired.

The main opportunity areas are lactose-free formulations, orally disintegrating or mini-tablet formats, fixed-dose combinations, low-dose titration products, and manufacturing platforms that reduce tablet weight and improve content uniformity. Regulatory and patent barriers are materially lower than for a new chemical entity, but clinical and commercial barriers remain significant because pioglitazone is an established generic medicine with broad price competition.

What is Actos and how is pioglitazone supplied?

Actos is Takeda's brand of pioglitazone hydrochloride, a thiazolidinedione approved for glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. Pioglitazone activates peroxisome proliferator-activated receptor gamma, or PPAR-gamma, and improves insulin sensitivity.

The US product is supplied as immediate-release film-coated tablets in 15 mg, 30 mg, and 45 mg strengths. The reference product does not rely on an advanced delivery system, sustained-release matrix, lipid carrier, or biologic excipient platform.

Attribute	Actos
Active ingredient	Pioglitazone hydrochloride
Therapeutic class	Thiazolidinedione antidiabetic
Dosage form	Immediate-release film-coated tablet
US strengths	15 mg, 30 mg, 45 mg
Original sponsor	Takeda Pharmaceuticals
US approval	1999
Administration	Once daily, with or without food
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable
Primary current competition	Generic pioglitazone tablets and fixed-dose combinations

The reference product labeling identifies lactose monohydrate, hydroxypropyl cellulose, carboxymethylcellulose calcium, and magnesium stearate in the tablet core. The film coating includes hypromellose, polyethylene glycol, talc, titanium dioxide, and colorants that vary by strength.[1]

What excipients are used in Actos tablets?

Actos uses a conventional direct-compression or wet-granulation-style excipient architecture, although the exact manufacturing process is not fully disclosed in the commercial label.

Actos tablet core

The principal core excipients are:

Excipient	Likely formulation function
Lactose monohydrate	Diluent and tablet-mass former
Hydroxypropyl cellulose	Binder and granulation aid
Carboxymethylcellulose calcium	Disintegrant
Magnesium stearate	Lubricant

The low dose of pioglitazone hydrochloride relative to total tablet mass makes the diluent and binder system commercially important. The formulation must maintain dose uniformity across three strengths while providing acceptable hardness, friability, disintegration, and dissolution.

Lactose is the most commercially relevant component because it is inexpensive, widely available, and well established in oral solid-dose manufacturing. Its use also creates a straightforward product-development opportunity for manufacturers seeking lactose-free or reduced-lactose alternatives.

Actos film coating

The coating system contains hypromellose, polyethylene glycol, talc, titanium dioxide, and strength-specific colorants. The coating provides identification, handling properties, taste masking, and protection against surface abrasion.

Because the tablet is immediate release, the coating should not materially delay drug release. A generic manufacturer can generally use a different coating composition if the finished product meets applicable quality and bioequivalence requirements.

Excipient attributes that matter commercially

For pioglitazone, the relevant excipient performance attributes include:

• Particle-size distribution and flowability.
• Blend uniformity at low drug loading.
• Moisture sensitivity.
• Lubricant sensitivity.
• Disintegration time.
• Dissolution similarity to the reference product.
• Coating adhesion and color consistency.
• Compatibility with high-speed compression.
• Supply continuity and regional regulatory acceptance.

The active ingredient is not present at a high mass fraction. That increases the importance of powder segregation control and blend sampling strategy. An excipient supplier that can provide engineered lactose, co-processed filler-binder systems, or validated low-dose blending technology may create more value than a supplier offering a conventional commodity grade.

When did Actos lose patent and market exclusivity?

Actos lost meaningful US compound exclusivity in 2011. The core pioglitazone patent was US Patent No. 4,287,200, which covered the compound and related thiazolidinedione chemistry. The patent expired in 2011 after applicable term adjustments and extensions were exhausted.[2]

Milestone	Approximate date
Pioglitazone compound patent issued	1981
US Actos approval	July 1999
Pediatric exclusivity period	2011
Core US patent expiry and generic-entry period	2011
Generic pioglitazone availability	Beginning in 2012 in the United States
Current commercial position	Mature generic market

Actos also had later patents and regulatory exclusivity associated with combination products and uses. Those rights did not preserve broad exclusivity for immediate-release pioglitazone monotherapy after the compound patent expired.

The commercial implication is clear: an excipient strategy must support a differentiated generic, a combination product, or a lifecycle product. It cannot rely on exclusivity for the conventional Actos tablet itself.

What is the Orange Book status of Actos?

The FDA Orange Book identifies approved drug products, therapeutic equivalence information, and, where applicable, listed patents and exclusivity.[2] Conventional pioglitazone tablets are subject to generic substitution and are not protected by an active composition-of-matter patent comparable to the original Actos estate.

The Orange Book relevance differs by product:

Product category	Orange Book position	Excipient strategy implication
Actos 15 mg, 30 mg, 45 mg tablets	Mature reference product	Bioequivalent generic formulation is the baseline
Generic pioglitazone tablets	ANDA products with therapeutic-equivalence evaluations	Low-cost, scalable excipient system is critical
Pioglitazone/metformin products	Separate product-specific approvals and patent histories	Combination-specific formulation and patent review required
Pioglitazone/glimepiride products	Separate combination product	Excipient compatibility and dose-ratio control matter
Modified-release or novel delivery products	Product-specific regulatory pathway	Potential for formulation or method-of-use patenting

What formulations are protected by Actos-related patents?

The strongest historical rights were directed to pioglitazone itself and, in some cases, combination therapies or therapeutic uses. The ordinary Actos tablet excipient package is unlikely to provide meaningful standalone patent protection today.

A commercial formulation patent would need to claim a technical feature that is not inherent in every pioglitazone tablet. Examples could include:

• A defined lactose-free composition with specified excipient ratios.
• A co-processed filler-binder that improves blend uniformity.
• A rapidly disintegrating tablet with a defined dissolution profile.
• A low-dose tablet with improved dose-content uniformity.
• A taste-masked oral dosage form.
• A fixed-dose combination with defined release characteristics.
• A moisture-protective package and formulation that materially improves stability.
• A pediatric or geriatric dosage form with clinically useful administration advantages.

A claim that merely substitutes one conventional diluent for lactose may face enablement, obviousness, and commercial-value challenges. Stronger protection is more likely where the excipient system produces a demonstrated benefit, such as a substantial dissolution improvement, reduced tablet size, superior stability, or better adherence.

How strong is the Actos patent estate for excipient opportunities?

The Actos estate is weak for conventional excipient substitution and stronger for selected lifecycle applications.

Opportunity	Patent strength	Regulatory burden	Commercial attractiveness
Standard lactose-based generic	Low	Low to moderate	Low margin, high volume
Lactose-free generic	Moderate if technically differentiated	Moderate	Moderate
Orally disintegrating tablet	Moderate	Moderate	Moderate
Mini-tablet or sprinkle formulation	Moderate	Moderate	Niche
Pioglitazone/metformin combination	Moderate	Moderate	Moderate to high
Sustained-release formulation	Potentially moderate	High	Uncertain
Pediatric formulation	Moderate	High	Limited market
Novel excipient platform	Potentially high	High	Depends on clinical benefit

A new formulation patent would generally require a meaningful technical relationship between composition and performance. The mere presence of an alternative excipient is unlikely to create durable protection unless the resulting product has a measurable and defensible advantage.

What commercial opportunities exist for Actos excipient innovation?

Lactose-free pioglitazone tablets

A lactose-free formulation is the most direct excipient opportunity. Replacement options include microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch-based systems, and co-processed excipients.

The product would target patients or prescribers seeking to avoid lactose, although the medical need is narrower than in gastrointestinal products or pediatric formulations. The business case depends on whether lactose-free status supports formulary differentiation, private-label supply, tender access, or a premium cash-pay product.

The technical risks include:

• Higher tablet weight.
• Different compactability.
• Slower or faster disintegration.
• Altered dissolution.
• Greater sensitivity to lubricant level.
• New moisture and stability behavior.

Orally disintegrating and low-swallowing-burden products

Pioglitazone is taken chronically, and some patients have difficulty swallowing conventional tablets. An orally disintegrating tablet could use mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The product would need to address the bitter or otherwise unacceptable taste of the drug. A fast-disintegrating format without adequate taste masking would have limited value.

Commercial differentiation could come from:

• Reduced water requirement.
• Smaller tablet size.
• Faster disintegration.
• Unit-dose packaging.
• Easier administration in older adults.
• Use in patients with dysphagia.

The principal risk is that a new dosage form may require more than a routine ANDA approach if the formulation changes exposure or drug-release behavior.

Fixed-dose combinations

Pioglitazone has been combined with metformin and sulfonylureas. Combination products create a stronger commercial case for formulation engineering because they reduce pill burden and allow dose-ratio differentiation.

Excipient issues include:

• Different dose loads between the two active ingredients.
• Chemical and physical compatibility.
• Distinct dissolution requirements.
• Segregation risk.
• Compression behavior.
• Potential interactions with moisture.
• Multi-strength manufacturing complexity.

A bilayer tablet, multilayer tablet, or controlled-release combination can create additional intellectual-property opportunities. These products also face competition from established combination generics and other diabetes therapies, including DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.

Low-dose titration and geriatric formats

Pioglitazone dosing often begins at a lower dose in patients with risk factors for fluid retention or other adverse effects. A 7.5 mg or other low-dose product could improve dose titration, provided there is a clinical and commercial rationale.

Excipient challenges are pronounced at low dose because content uniformity becomes more difficult. A co-processed excipient or ordered-mixture technology could support a defensible formulation patent if it produces validated uniformity and manufacturing advantages.

Supply-chain and regional excipient strategies

A manufacturer can create value without changing the final product profile by using:

• Dual-source excipients.
• Regional compendial grades.
• Lower-cost local suppliers.
• Moisture-controlled packaging.
• Direct-compression grades that reduce processing steps.
• Excipient specifications designed for global regulatory filings.

For a mature generic, cost of goods and supply reliability are often more important than a small pharmacokinetic advantage. A formulation that uses broadly accepted compendial excipients and avoids unusual materials may have the strongest global launch profile.

How does Actos compare with generic pioglitazone products?

Generic pioglitazone products compete primarily on price, availability, therapeutic equivalence, and supply reliability. A generic does not need to copy every excipient in Actos. It must meet the applicable quality and bioequivalence requirements and comply with labeling and inactive-ingredient rules.[3]

Factor	Actos reference product	Conventional generic	Differentiated excipient product
Active ingredient	Pioglitazone hydrochloride	Same	Same
Release type	Immediate release	Usually immediate release	May be immediate release or modified
Excipient freedom	Original formulation	Broad, subject to regulatory limits	Broad, with technical justification
Price position	Historically premium	Low-cost	Potentially premium or contract-priced
Patent protection	Historical compound and product estate	Usually non-infringing formulation	Possible new formulation claims
Regulatory pathway	NDA	ANDA or applicable local pathway	ANDA, 505(b)(2), or regional equivalent depending on design
Commercial differentiation	Brand recognition	Price and availability	Administration, stability, combination, or manufacturing benefit

The most attractive products are not necessarily the most technically complex. A lactose-free tablet with high manufacturing robustness may offer a better return than a novel sustained-release product requiring additional clinical studies.

Which companies are challenging or competing with Actos?

Generic competition has included large multinational manufacturers and regional generic companies. The relevant competitive set includes manufacturers of:

• Pioglitazone hydrochloride tablets.
• Pioglitazone/metformin tablets.
• Pioglitazone/glimepiride tablets.
• Other insulin-sensitizing products.
• Newer diabetes medicines with stronger cardiovascular or weight-related positioning.

The commercial threat to a new pioglitazone formulation is not limited to other pioglitazone products. SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, insulin products, and low-cost metformin all compete for treatment decisions.

An excipient innovation must therefore produce a benefit that matters in prescribing, adherence, payer contracting, or manufacturing. A reformulation with no visible clinical or operational advantage is unlikely to displace low-cost generic tablets.

What FDA regulatory pathway applies to an excipient-focused pioglitazone product?

A conventional immediate-release generic normally follows the ANDA pathway. FDA review focuses on pharmaceutical equivalence, bioequivalence, quality, manufacturing controls, stability, and labeling requirements.[3]

A different pathway may apply where the product introduces a clinically meaningful change:

Product design	Likely pathway consideration
Same strength and immediate release with alternative excipients	ANDA
New dosage form with different administration characteristics	ANDA or 505(b)(2), depending on design
Modified release or materially different exposure	Potentially 505(b)(2) or new NDA strategy
New indication or pediatric claim	Separate clinical and regulatory requirements
Fixed-dose combination	Product-specific application and combination-product requirements

FDA's inactive-ingredient database can help determine whether proposed excipients and routes of administration have prior precedent.[4] Prior use does not eliminate the need to assess maximum daily exposure, route-specific safety, impurity controls, and patient populations.

What generic entry risks exist for an Actos formulation?

Generic entry risk is high for the conventional product because the active ingredient is old, the dosage form is simple, and multiple suppliers can manufacture standard tablets.

Risk levels differ by strategy:

• Standard tablet: very high generic price pressure.
• Lactose-free tablet: moderate differentiation, limited protection unless patented.
• Orally disintegrating tablet: moderate risk from substitute dosage forms.
• Fixed-dose combination: moderate risk from existing combination generics.
• Novel modified-release product: lower direct substitution risk but higher development and regulatory risk.
• Excipient platform sold to multiple manufacturers: lower product-specific risk but greater pricing pressure from competing suppliers.

Paragraph IV litigation is principally relevant when a manufacturer seeks approval of a product that references an NDA with listed patents. For the original Actos monotherapy product, the central compound patent has expired. A new formulation or combination product could create a separate Paragraph IV landscape if it has active Orange Book-listed patents.

What manufacturing and intellectual-property barriers remain?

The main manufacturing barrier is not synthesis of pioglitazone. It is consistent low-dose blending and tablet production at commercial scale.

Critical process controls include:

1. API particle-size control.
2. Ordered addition and blending sequence.
3. Segregation prevention.
4. Lubrication-time control.
5. Compression-force monitoring.
6. Tablet weight and hardness control.
7. Coating uniformity.
8. Dissolution control across strengths.
9. Stability under regional humidity conditions.

Potential intellectual-property barriers include:

• Patents on specific excipient ratios.
• Co-processed excipient claims.
• Bilayer or multilayer tablet architecture.
• Modified-release polymers.
• Taste-masking systems.
• Combination-product dose arrangements.
• Packaging and moisture-control systems tied to stability performance.

Freedom-to-operate analysis should cover active patents, abandoned applications, continuation practice, foreign counterparts, and patents owned by excipient suppliers. The absence of an Orange Book listing does not eliminate non-Orange-Book formulation risk.

What revenue exposure and market positioning should investors assess?

Actos was historically a major Takeda product, with annual sales reaching several billion dollars before generic erosion and competitive shifts. The value of the branded franchise did not transfer directly to excipient suppliers after patent expiry. Genericization shifted value toward volume, cost control, contract manufacturing, and combination products.[5]

For an excipient company, revenue exposure depends on its position in the value chain:

Business model	Revenue profile
Commodity lactose or magnesium stearate	High volume, low margin
Engineered filler-binder	Moderate volume, higher margin
Proprietary co-processed excipient	Lower volume, potential premium
Formulation development partnership	Milestone and development revenue
Finished-dose pioglitazone product	Price-sensitive, scale-dependent
Fixed-dose combination product	Greater differentiation, higher development cost

The strongest commercial case is a platform that can be used in pioglitazone and other low-dose, immediate-release products. That expands the addressable market beyond Actos and reduces dependence on one mature molecule.

Key Takeaways

• Actos is an immediate-release pioglitazone tablet using conventional excipients.
• The reference formulation contains lactose monohydrate, hydroxypropyl cellulose, carboxymethylcellulose calcium, magnesium stearate, and a standard film-coating system.
• Broad US exclusivity ended in 2011, and conventional pioglitazone tablets are exposed to generic competition.
• The strongest excipient opportunities are lactose-free tablets, orally disintegrating formats, low-dose products, fixed-dose combinations, and engineered excipient systems.
• A simple excipient substitution is unlikely to support strong patent protection without a measurable technical benefit.
• Standard generic tablets offer volume but limited margin.
• Combination products and administration-focused formulations offer greater differentiation but carry higher regulatory and development risk.
• Pioglitazone is a small-molecule drug, so biosimilar risk does not apply.
• Manufacturing control over low-dose blend uniformity, dissolution, and stability is central to product quality and commercial reliability.
• A platform excipient applicable to multiple generic drugs is more attractive than an Actos-only formulation.

FAQs

Can lactose be removed from an Actos generic?

Yes. A manufacturer can develop a lactose-free pioglitazone tablet using alternative diluents and binders, subject to quality, bioequivalence, inactive-ingredient, and labeling requirements.

Is an excipient patent enough to block generic pioglitazone competition?

Usually not. A strong blocking position requires a valid, enforceable claim covering a commercially necessary formulation feature. A routine diluent substitution generally provides limited protection.

Is pioglitazone suitable for an orally disintegrating tablet?

Technically, yes. The main development issue is taste masking, followed by disintegration, dose uniformity, stability, and demonstration of comparable drug performance.

Are Actos and pioglitazone subject to biosimilar competition?

No. Pioglitazone is a chemically synthesized small molecule. Competition occurs through generic-drug pathways, not biosimilar pathways.

Which pioglitazone lifecycle strategy has the best commercial potential?

Fixed-dose combinations and administration-focused products generally offer more differentiation than a standard tablet. The best strategy depends on development cost, payer acceptance, patentability, and the ability to demonstrate a benefit beyond excipient substitution.

References

1. U.S. Food and Drug Administration. (n.d.). Actos (pioglitazone hydrochloride) tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDAs for certain highly soluble drugs: Product-specific guidance for industry.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. Takeda Pharmaceutical Company Limited. (2011). Annual report 2011.